Monoclonal antibodies in oncology therapeutics: Present and future indications

Expert Opinion on Biological Therapy

Volumn 13, Issue 2, 2013, Pages 269-282

  Bhutani, Divaya ^a   Vaishampayan, Ulka N ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer therapy; clinical use; mechanism of action; monoclonal antibodies; novel targets for monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DACETUZUMAB; DARATUMUMAB; DOXORUBICIN; ELOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIGITUMUMAB; GLYCOPROTEIN GP 100; IPILIMUMAB; IRINOTECAN; MILATUZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PREDNISONE; RITUXIMAB; SILTUXIMAB; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; B CELL LYMPHOMA; BACTERIAL INFECTION; BLOOD TOXICITY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONGESTIVE HEART FAILURE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART INFARCTION; HEMOPTYSIS; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYCOSIS; NATURAL KILLER CELL; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PNEUMOCYSTIS PNEUMONIA; PROSTATE CANCER; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; T CELL LYMPHOMA; TREATMENT INDICATION; TUMOR NECROSIS; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT ACTIVATION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84872183239     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.758705     Document Type: Review

References (112)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
2. Sainsbury JR, Malcolm AJ, Appleton DR. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985;38(11):1225-8 (Pubitemid 16215034)
3. Saeki T, Salomon DS, Johnson GR. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25(6):240-9
4. Normanno N, De Luca A, Bianco C. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006;366(1):2-16 (Pubitemid 43199589)
5. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1(11):1311-18
6. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95(4):1897-904
7. Baselga J, Norton L, Masui H, Pandiella A. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85(16):1327-33 (Pubitemid 23249725)
8. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637-42 (Pubitemid 23304392)
9. Klapper LN, Vaisman N, Hurwitz E, et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14(17):2099-109 . This provides the evidence for mechanism of action of trastuzumab by blocking interaction between various HER receptors. (Pubitemid 27237013)
10. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27 (Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20(9):3210-23 (Pubitemid 30215033)
11. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-Activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006;29(4):388-97 (Pubitemid 44288951)
12. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64(13):4664-9 (Pubitemid 38856941)
13. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9(16 Pt 1):5866-73 (Pubitemid 38018069)
14. Clynes RA, Towers TL, Presta LG. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6(4):443-6 (Pubitemid 30208162)
15. Koene HR, Kleijer M, Algra J. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90(3):1109-14 Pre-clinical data showing influence of FcGamma receptor polymorphisms on antibody binding to the targets. (Pubitemid 27314146)
16. Cartron G, Dacheux L, Salles G. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8 (Pubitemid 34525533)
17. Rodriguez J, Zarate R, Bandres E. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012;48(12):1774-80
18. Choi BD, Cai M, Bigner DD. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011;11(7):843-53
19. Topp M, Goekbuget N, Zugmaier G. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL [abstract # 6500]. ASCO; 2012
20. Topp MS, Kufer P, Gokbuget N. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
21. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998 Mar;50(1):59-87 (Pubitemid 28158842)
22. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-7 (Pubitemid 36900094)
23. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006;91(2):176-83
24. Zent CS, Chen JB, Kurten RC. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28(5):495-507 (Pubitemid 38453062)
25. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24(3):263-71 (Pubitemid 32479718)
26. Van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807-11 Provides mechanism of action of side effects of rituximab. (Pubitemid 34042897)
27. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27 (Pubitemid 46202320)
28. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64 (Pubitemid 26272076)
29. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56(17):4032-9 (Pubitemid 26284756)
30. Willett CG, Boucher Y, di Tomaso E. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7 (Pubitemid 38524883)
31. Hodge DR, Peng B, Cherry JC. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005;65:4673-82 (Pubitemid 40740803)
32. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85(4):863-72
33. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9(13):4653-64
34. Rossi JF, Negrier S, James ND. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103(8):1154-62
35. Coward J, Kulbe H, Chakravarty P. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17(18):6083-96
36. Hunsucker SA, Magarotto V, Kuhn DJ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011;152:579-92
37. Lewis Phillips GD, Li G, Dugger DL. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68(22):9280-90
38. Pasquetto MV, Vecchia L, Covini D. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34(9):611-28
39. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20(8):1131-49
40. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-44 One of the earlier studies proving single agent and combination activity of cetuximab.
41. Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-64
42. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
43. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67(6):2643-8 . Provides mechanism of resistance to EGFR inhibitors in patients with K-ras mutations. (Pubitemid 46548951)
44. Van Cutsem E, Kohne CH, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
45. Douillard JY, Siena S, Cassidy J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-704
46. Vermorken JB, Mesia R, Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
47. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92 (Pubitemid 32222155)
48. Vogel CL, Cobleigh MA, Tripathy D. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Clin Oncol 2002;20(3):719-26 (Pubitemid 34111379)
49. Burstein HJ, Keshaviah A, Baron AD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110(5):965-72 (Pubitemid 47312860)
50. Robert N, Leyland-Jones B, Asmar L. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24(18):2786-92 (Pubitemid 46630577)
51. Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20 (Pubitemid 43290919)
52. Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84 (Pubitemid 41464706)
53. Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97 . Provides evidence for efficacy of trastuzumab in HER-2 positive gastric cancer.
54. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42 (Pubitemid 38702844)
55. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50 (Pubitemid 44917502)
56. Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11 (Pubitemid 350296300)
57. Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
58. Miles DW, Chan A, Dirix LY, Cortes J. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
59. Johnson DH, Fehrenbacher L, Novotny WF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91 (Pubitemid 41095154)
60. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-Analysis. JAMA 2011;305(5):487-94
61. Colombat P, Salles G, Brousse N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97(1):101-6 (Pubitemid 32061248)
62. Marcus R, Imrie K, Belch A. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23 (Pubitemid 40223656)
63. Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32 (Pubitemid 41742196)
64. Feugier P, Van Hoof A, Sebban C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23(18):4117-26 (Pubitemid 46211317)
65. Habermann TM, Weller EA, Morrison VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121-7 (Pubitemid 46638950)
66. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19(8):2153-64 (Pubitemid 32366969)
67. Keating MJ, O'Brien S, Albitar M. Early results of a chemoimmunotherapy regimen of fludarabine, Cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88 (Pubitemid 46211313)
68. Byrd JC, Rai K, Peterson BL. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105(1):49-53 (Pubitemid 40053062)
69. Abdulla NE, Ninan MJ, Markowitz AB. Rituximab: current status as therapy for malignant and benign hematologic disorders. BioDrugs 2012;26(2):71-82
70. Rai KR, Freter CE, Mercier RJ. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20(18):3891-7
71. Keating MJ, Flinn I, Jain V. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99(10):3554-61 (Pubitemid 34534522)
72. Stilgenbauer S, Zenz T, Winkler D. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27(24):3994-4001
73. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 Provides Mechanism Of Action Of CTLA-4. (Pubitemid 46160986)
74. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27 (Pubitemid 350250330)
75. Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
76. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13(1):16-24 (Pubitemid 351206693)
77. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002;1:339-53 (Pubitemid 41039136)
78. Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636-44 (Pubitemid 46398739)
79. Haluska P, Shaw HM, Batzel GN. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13(19):5834-40 (Pubitemid 47583908)
80. Karp DD, Paz-Ares LG, Novello S. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27(15):2516-22
81. Schmitz S, Kaminsky-Forrett MC, Henry S. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 2012;23(8):2153-61
82. Malempati S, Weigel B, Ingle AM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30(3):256-62
83. Tolcher AW, Sarantopoulos J, Patnaik A. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27(34):5800-7
84. Atzori F, Tabernero J, Cervantes A. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17(19):6304-12
85. Voorhees PM, Chen Q, Kuhn DJ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78 (Pubitemid 350075037)
86. Van Rhee F, Fayad L, Voorhees P. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28(23):3701-8 Shows a high efficacy of siltuximab in Castleman's disease.
87. . Shows a high efficacy of siltuximab in Castleman's disease. 87. Dorff TB, Goldman B, Pinski JK. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab) A Monoclonal Antibody Against Interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16(11):3028- 34
88. Gille H, Kowalski J, Li B. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276(5):3222-30
89. Spratlin JL, Cohen RB, Eadens M. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
90. Iwai Y, Ishida M, Tanaka Y. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7 . Provides Mechanism For The PD-L1 And PD-1 pathway.
91. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56(5):739-44 . Provides mechanism for the PD-L1 and PD-1 pathway.
92. Thompson RH, Kuntz SM, Leibovich BC. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381-4
93. Brahmer JR, Drake CG, Wollner I. Phase I study of single-Agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-74
94. Berger R, Rotem-Yehudar R, Slama G. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14(10):3044-51
95. Benson DM Jr., Bakan CE, Mishra A. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
96. Mkrtichyan M, Najjar YG, Raulfs EC. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41(10):2977-86
97. Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011;5:45-53
98. Wierda WG, Padmanabhan S, Chan GW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011;118(19):5126-9
99. Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12(3):343-51
100. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51(5):747-54
101. Burris HA III, Rugo HS, Vukelja SJ. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-404
102. Chen R, Gopal AK. Results of a Pivotal Phase 2 Study of Brentuximab vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2010;116:283 . Initial study showing a high efficacy of brentuximab in relapsed HD.
103. Advani A, Coiffier B, Czuczman MS. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28(12):2085-93
104. Kantarjian H, Thomas D, Jorgensen J. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13(4):403-11 A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer. NCT01283373
105. Gudas M, An Z, Morrison RK, Morrison KJ. ASG-5ME: a novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers [abstract # 230]. ASCO; 2010
106. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52(12):3402-8
107. Kennedy AD, Beum PV, Solga MD. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172(5):3280-8 (Pubitemid 38263720)
108. de Weers M, Tai YT, van der Veer MS. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840-8
109. Alinari L, Yu B, Christian BA, Yan F. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117(17):4530-41
110. Lewis TS, McCormick RS, Stone IJ. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 2011;25(6):1007-16
111. Jakubowiak AJ, Benson DM, Bensinger W. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012
112. Sutherland MK, Yu C, Lewis TS. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2009;1(5):481-90